Format

Send to

Choose Destination
Drug Discov Today. 2015 Jul;20(7):838-47. doi: 10.1016/j.drudis.2015.02.008. Epub 2015 Feb 26.

Bispecific antibodies.

Author information

1
Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany. Electronic address: roland.kontermann@izi.uni-stuttgart.de.
2
Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Penzberg, Penzberg, Germany. Electronic address: ulrich.brinkmann@roche.com.

Abstract

Bispecific antibodies (bsAbs) combine specificities of two antibodies and simultaneously address different antigens or epitopes. BsAbs with 'two-target' functionality can interfere with multiple surface receptors or ligands associated, for example with cancer, proliferation or inflammatory processes. BsAbs can also place targets into close proximity, either to support protein complex formation on one cell, or to trigger contacts between cells. Examples of 'forced-connection' functionalities are bsAbs that support protein complexation in the clotting cascade, or tumor-targeted immune cell recruiters and/or activators. Following years of research and development (R&D), the first bsAb was approved in 2009. Another bsAb entered the market in December 2014 and several more are in clinical trials. Here, we describe the potentials of bsAbs to become the next wave of antibody-based therapies, focusing on molecules in clinical development.

PMID:
25728220
DOI:
10.1016/j.drudis.2015.02.008
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center